Moderna starts late-stage trial of bird flu vaccine in US, UK

Moderna has started a late-stage U.S. and UK trial of its experimental bird flu vaccine, marking the first mRNA-based pandemic bird flu vaccine to reach Phase 3 testing. The update is a meaningful development for Moderna’s pipeline and supports the company’s vaccine platform, though it is still an early commercialization step. The news is likely to modestly influence Moderna shares and sentiment across the vaccine/biotech group.

Analysis

Moderna has started a late-stage U.S. and UK trial of its experimental bird flu vaccine, marking the first mRNA-based pandemic bird flu vaccine to reach Phase 3 testing. The update is a meaningful development for Moderna’s pipeline and supports the company’s vaccine platform, though it is still an early commercialization step. The news is likely to modestly influence Moderna shares and sentiment across the vaccine/biotech group.